MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals Inc. demonstrates a strong financial growth trajectory, with projected sales for volixibat anticipated to rise significantly from $18 million in 2027 to $854 million by 2033. The company's core business revenues are estimated to surpass $1 billion, supported by robust projected growth for Livmarli, which is expected to achieve over $800 million in revenue by 2031, fueled by increased diagnosis rates and expanding indications. Additionally, Mirum's existing approved products, Livmarli, Cholbam, and Ctexli, are showing promising growth trends, particularly Livmarli, which is forecasted to experience a 69% year-over-year revenue increase in FY25, attributed to a steady influx of new patients and heightened awareness of the underlying conditions.

The financial outlook for Mirum Pharmaceuticals Inc. appears negative due to several fundamental risks that could impede its growth and overall success. Specifically, any unexpected safety issues or reduced efficacy related to its medications, particularly Livmarli, could lead to significant setbacks in clinical trials, diminishing revenue potential. Additionally, greater than anticipated operating expenses and cash burn may necessitate more frequent equity issuances at less favorable valuations, further straining the company’s financial position.